CNVs have been reported to disrupt genes known to be involved in breast cancer susceptibility, including BRCA1, BRCA2, TP53 and CHEK2 [4], and could similarly alter other genes involved in pathways related to breast cancer susceptibility. This evidence concerns the gene BRCA2 and breast carcinoma.